Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations

A HERITAGE OF INNOVATION AND LEADERSHIP

Lantheus Medical Imaging, a global leader in developing, manufacturing, selling, and distributing innovative diagnostic imaging agents, is dedicated to creating and providing medical imaging solutions to improve the treatment of human disease.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

Lantheus Medical Imaging to Present Data on Novel PET Cardiac Imaging Agent Flurpiridaz F 18 at ASNC Annual Scientific Session

N. BILLERICA, Mass. (September 18, 2014) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced that data demonstrating significant reductions in radiation exposure and improved image quality with flurpiridaz F 18 myocardial perfusion imaging (MPI) as compared with single photon emission computed tomography (SPECT) will be presented in a poster presentation at the American Society of Nuclear Cardiology (ASNC) 19th Annual Scientific Session, being held September 18-21, 2014 in Boston. The data were collected in the first of the Company’s Phase 3 clinical trials. Flurpiridaz F 18 is an investigational positron emission tomography (PET) MPI agent currently in Phase 3 development.

click here for the press release

 

 

Company Spotlight

Webcast Image Webcast
Imperial Capital Global Opportunities Conference
Thursday, September 18, 2014 at 9:30 a.m. ET
© 2014 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map